Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00382070 · FLOW

Participant flow

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer · Source last updated 2024-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive oral letrozole once daily for up to 5 years. Letrozole: Letrozole 2.5 mg taken orally once daily for 5 years
    id
    FG000
    title
    Group 2 Letrozole
  2. description
    Patients receive oral placebo once daily for up to 5 years. Placebo: Placebo tablet taken orally once daily for 5 years
    id
    FG001
    title
    Group 1 Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        17
      2. group Id
        FG001
        num Subjects
        19
      type
      No follow up data mapped to Other
    2. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        0
      type
      Patient not at risk for primary endpoint mapped to Other
    3. reasons
      1. group Id
        FG000
        num Subjects
        9
      2. group Id
        FG001
        num Subjects
        11
      type
      No clinical assessment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        1983
      2. group Id
        FG001
        num Subjects
        1983
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1950
      2. group Id
        FG001
        num Subjects
        1953
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        33
      2. group Id
        FG001
        num Subjects
        30
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive oral letrozole once daily for up to 5 years. Letrozole: Letrozole 2.5 mg taken orally once daily for 5 years
    id
    FG000
    title
    Group 2 Letrozole
  2. description
    Patients receive oral placebo once daily for up to 5 years. Placebo: Placebo tablet taken orally once daily for 5 years
    id
    FG001
    title
    Group 1 Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        17
      2. group Id
        FG001
        num Subjects
        19
      type
      No follow up data mapped to Other
    2. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        0
      type
      Patient not at risk for primary endpoint mapped to Other
    3. reasons
      1. group Id
        FG000
        num Subjects
        9
      2. group Id
        FG001
        num Subjects
        11
      type
      No clinical assessment
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        1983
      2. group Id
        FG001
        num Subjects
        1983
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1950
      2. group Id
        FG001
        num Subjects
        1953
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        33
      2. group Id
        FG001
        num Subjects
        30
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice